[ORGANIZATION]
Lucid Psycheceuticals Inc.
Featured in 1 tracked story · first seen
Situations
Quantum BioPharma MS therapy development
5 clusters · 9 sources · last updated
Latest: Quantum BioPharma receives ‘Buy’ rating for Lucid-MS candidate
In July 2026, Quantum BioPharma announced that its proprietary multiple‑sclerosis candidate LUCID‑MS had completed Phase 1 studies in healthy volunteers with a favorable safety profile and had filed an IND with the U.S.